Skip to main content
Equibles

PPBT · Purple Biotech Ltd. · Metrics

Track PPBT — free

Use PPBT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PPBT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.56 +0.07 (+4.70%) At close · Nov 12
Rebalance outlook locked
Market Cap
$2.54M
Shares
1.63M
Volume · Nov 12 67.46K Avg daily vol (3M) 1.24M

PPBT metrics

44 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.56
Market cap
$2.54M

Price action

23 metrics
Price change (1W)
+22.6%
Price change (30D)
+9.6%
Price change (3M)
+0.7%
Price change (6M)
-62.3%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
98.5%
Annualized volatility (3M)
86.0%
Implied volatility (30D)
204.9%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.1
RSI (14D)
64.2
Price vs SMA 50
+6.0%
Price vs SMA 200
—
Avg volume (3M)
1.24M
Relative volume
0.0
Average dollar volume
$2.44M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.63M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.2
reciprocal yield 400.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-1,261.2%
Trailing 12 months
Net margin
2,799.9%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$104.51

Growth

11 metrics
Revenue growth YoY
+0.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
-99.9%
Shares change YoY
+259.5%
Year over year · more shares
Revenue CAGR (3Y)
+115.4%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
-95.2%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-271.6%
Return on assets
-150.2%
Debt / equity
—
Current ratio
1.3
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$8.72M
Total assets
$17.57M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
13
13F filer change QoQ
-2
Institutional ownership
5.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+12.3%
Holder tenure
2.2
Price vs estimated holder cost
-58.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
1.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
43 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1614744 CUSIP 74638P307 13F (30d) 8 filings 8 filers Visit website Investor relations